CluenexHow does the ENHANZE royalty model work?
Halozyme Therapeutics operates a specialty drug delivery business centered on its recombinant human hyaluronidase enzyme, known commercially as ENHANZE (rHuPH20). The enzyme temporarily breaks down hyaluronan, a naturally occurring sugar gel in human skin and subcutaneous tissue, allowing large volumes of biologic medications to disperse rapidly into the bloodstream.
Biologic drugs are complex therapies made from living cells, such as monoclonal antibodies used in oncology and immunology. Traditionally, these large molecules require intravenous (IV) infusions in an infusion clinic that take between one and eight hours. By combining their therapies with ENHANZE, pharmaceutical partners convert intravenous treatments into subcutaneous injections delivered under the skin with a simple needle in three to eight minutes.
Halozyme monetizes this convenience through three revenue streams:
- Royalties: Licensees pay Halozyme a royalty, typically ranging between 3% and 5% of net sales, on commercialized products that use ENHANZE.
- Product sales: Halozyme manufactures and sells bulk rHuPH20 active pharmaceutical ingredient (API) to its partners for use in formulation.
- Milestones and licensing fees: Upfront access payments and cash bonuses triggered when partner drugs hit clinical trial, regulatory, or sales hurdles.
Royalties form the vast majority of company profits because they carry negligible direct operating costs. In the healthcare sector, where the median Healthcare gross margin is 65.2%, Halozyme generates gross margins well above 80% because royalty checks drop almost entirely to operating profit.
When do Halozyme's core ENHANZE patents expire?
Halozyme faces a known expiration window for its foundational technology: its primary U.S. composition of matter patent for rHuPH20 expires in 2027, while its primary European manufacturing patent runs until March 6, 2029.
In the pharmaceutical industry, a patent cliff occurs when the primary legal monopoly protecting a high-margin drug expires, opening the market to generic copies and causing sales to plunge by 70% to 90%. For Halozyme, the risk is that rival biotechnology firms could produce biosimilar recombinant hyaluronidase after 2027, which would allow partners to drop Halozyme's API or pressure the company into slashing its royalty rates.
To counter this risk, Halozyme secured European Patent No. 4269578 in 2024, protecting ENHANZE manufacturing methods across 37 European countries until March 6, 2029. This patent ensures that licensees selling in Europe must maintain their agreed royalty rates through at least the first quarter of 2029, preventing immediate discount clauses from taking effect.
How co-formulation patents extend cash flows past 2027
Halozyme avoids an immediate post-2027 revenue collapse through co-formulation patents, which are collaboration patents filed jointly with drugmakers to cover the specific pairing of an active drug molecule and rHuPH20.
When a partner develops a subcutaneous version of an existing intravenous therapy, the two companies file specific intellectual property protecting the exact chemical formulation, dosing intervals, and injection volume of that combined therapy. Under standard ENHANZE licensing agreements, partners agree to pay full or tiered royalties until the expiration of the collaboration patent covering that specific product, or for a set contractual term (often 10 to 12 years from first commercial sale), regardless of when Halozyme's base enzyme patent expires.
| Partnered Biologic | Target Indication | Primary Licensee | U.S. Commercial Launch | Estimated Royalty Expiration Window |
|---|---|---|---|---|
| Darzalex Faspro (SC) | Multiple Myeloma | Janssen (Johnson & Johnson) | May 2020 | Mid-2032 (contractual 12-year term) |
| Phesgo | HER2+ Breast Cancer | Genentech (Roche) | June 2020 | Mid-2030 (co-formulation patent) |
| Vyvgart Hytrulo | Generalized Myasthenia Gravis | argenx | June 2023 | 2035 to early 2040s (combination patents) |
| Tecentriq SC | Non-Small Cell Lung Cancer | Roche | 2024 | Up to 2040 (subject to granted patents) |
| Ocrevus Zunovo (SC) | Multiple Sclerosis | Roche | September 2024 | 2034 to 2036 (10-year term / collaboration IP) |
Because blockbuster drugs like Janssen's Darzalex Faspro and Roche's Phesgo launched between 2020 and 2024, their contractual protections and combination patents shelter the majority of Halozyme's royalty baseline through at least 2030 to 2032. Understanding how combination exclusivity functions helps investors distinguish a real business deterioration from an ordinary value trap vs bargain.
What are the limits and legal vulnerabilities of the patent defense?
The co-formulation patent defense is not invulnerable, and investors face three structural legal and competitive challenges:
- Patent oppositions and revocations: In Europe, competitors routinely challenge secondary collaboration patents before the European Patent Office (EPO). For instance, oppositions against Janssen co-formulation patents for Darzalex SC created uncertainty regarding when European royalty rates would step down. While Halozyme's 2029 European manufacturing patent provides a baseline floor, patent challenges can shorten the tail of expected cash flows.
- Direct platform competition: Competitors are engineering alternative hyaluronidase platforms. South Korean biotech firm Alteogen developed a competing recombinant hyaluronidase (ALT-B4) and partnered with Merck to reformulate Keytruda (pembrolizumab) for subcutaneous delivery. Alteogen provides large pharmaceutical sponsors with an alternative vendor, reducing Halozyme's pricing leverage on future pipeline deals.
- Loss of underlying drug exclusivity: A co-formulation patent keeps generic drug delivery providers out, but it cannot prevent a partner's drug from facing competition if the core antibody loses exclusivity. If intravenous daratumumab faces biosimilar erosion in the late 2020s, overall treatment pricing could decline, pulling down absolute dollar royalty collections even if Halozyme keeps its agreed royalty percentage. Similar pipeline durability questions are explored in our look at Exelixis and the Cabometyx patent cliff.
To build a deeper moat, Halozyme has been investing in its next-generation modified hyaluronidase program, known as MDASE, alongside high-concentration delivery acquisitions like Hypercon and Surf Bio. MDASE features extended room-temperature stability and carries patent protections running into 2032 outside the U.S. and 2034 in the U.S., designed to incentivize partners to upgrade before older licenses expire. You can learn more about assessing competitive advantages in our guide to economic moat analysis.
What the current financial metrics show
Halozyme Therapeutics ($HALO) has experienced dramatic price momentum. As of November 2, 2026, the stock trades at $128.95, hovering just 1.7% below its 52-week high of $131.18 and well above its 52-week low of $61.63.
Over the past year, HALO shares have advanced 97.8% (up 91.6% year-to-date, 56.7% over three months, and 17.4% over one month), substantially outpacing the S&P 500 benchmark. By comparison, the S&P 500 closed November 2, 2026 at 7,541.40, having returned 10.3% over the trailing 12 months and 10.2% year-to-date, while dipping 2.3% over the past month.
Quarterly financial performance has shown notable variability in net earnings due to milestone timing, research expenses, and legal outlays, but recent quarters delivered substantial profit surprises:
- Quarter ending June 30, 2026: Diluted EPS of $2.28 beat analyst estimates of $1.87 by 21.75%.
- Quarter ending March 31, 2026: Diluted EPS of $1.60 beat estimates of $1.56 by 2.52%.
- Quarter ending December 31, 2025: Diluted EPS of -$0.24 missed estimates of $2.24 by -110.70%.
- Quarter ending September 30, 2025: Diluted EPS of $1.72 beat estimates of $1.66 by 3.56%.
Across the broader equity market, about 73% of firms exceed analyst earnings forecasts. Investors can examine Halozyme's historical valuation multiples, main risks, and business quality score on Halozyme's public stock page.
Halozyme reports its Q3 2026 earnings on November 5, 2026, after market close. For investors tracking market expectations ahead of the report, understanding revenue guidance mechanics and the composition of gross, operating, and net margins will help clarify how royalty volume flows into GAAP earnings.
What this means for you
If you manage your own investment portfolio and follow healthcare royalties, assessing Halozyme requires looking past single patent dates:
- Audit the partner concentration: Do not look at ENHANZE as one monolithic asset. Check what share of Halozyme's quarterly royalty income comes from Darzalex SC alone versus newer contributors like Vyvgart Hytrulo, Phesgo, and Ocrevus Zunovo.
- Track contract expirations, not just patent calendars: Contractual language often obligates a licensee to pay royalties for a fixed number of years (such as 10 or 12 years post-launch) regardless of whether a generic hyaluronidase is approved in that geography.
- Watch the upcoming earnings call for litigation updates: During the November 5, 2026 report, listen to management commentary regarding European patent oppositions, MDASE patent prosecutions, and competitive updates regarding alternative platforms like Alteogen.
- Separate base earnings from one-off payments: Strip out non-recurring milestone fees and professional legal charges when calculating ongoing operational cash flow.